2CB-Ind

2CB-Ind

2CB-Ind
Systematic (IUPAC) name
(5-bromo-4,7-dimethoxy-2,3-dihydro-1H-inden-1-yl)methanamine
Clinical data
Legal status
  • Uncontrolled
Routes Oral
Identifiers
CAS number  N
ATC code None
PubChem
ChemSpider  YesY
ChEMBL  YesY
Chemical data
Formula C12H16BrNO2 
Mol. mass 286.164 g/mol
 N   

2CB-Ind is a conformationally-restricted derivative of the phenethylamine hallucinogen 2C-B, discovered in 1974 by Alexander Shulgin. It acts as a moderately potent and selective agonist for the 5-HT2A and 5-HT2C receptors, but unlike the corresponding benzocyclobutene derivative TCB-2 which is considerably more potent than the parent compound 2C-B, 2CB-Ind is several times weaker, with racemic 2CB-Ind having a Ki of 47nM at the human 5-HT2A receptor, only slightly more potent than the mescaline analogue (R)-jimscaline.[1][2]

See also

References

  1. ^ McLean, TH, et al. (2006). "1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists". Journal of Medical Chemistry 49 (19): 5794–803.  
  2. ^ Braden, Michael Robert (2007). Towards a biophysical understanding of hallucinogen action (PhD.). Purdue University.